Cargando…

Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development

PURPOSE OF REVIEW: Design of an HIV vaccine that can induce broadly neutralizing antibodies (bnAbs) is a major goal. However, HIV bnAbs are not readily made by the immune system. Rather HIV bnAbs are disfavored by a number of virus and host factors. The purpose of the review is to discuss recent pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haynes, Barton F., Wiehe, Kevin, Alam, S. Munir, Weissman, Drew, Saunders, Kevin O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	IS AN HIV VACCINE STILL ACHIEVABLE?: Edited by Jim Kublin
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552807/ https://www.ncbi.nlm.nih.gov/pubmed/37751363 http://dx.doi.org/10.1097/COH.0000000000000820

Ejemplares similares

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
por: Stamatatos, Leonidas
Publicado: (2023)

Accelerating HIV vaccine development through meaningful engagement of local scientists and communities
por: Chinyenze, Kundai, et al.
Publicado: (2023)

Generating and measuring effective vaccine-elicited HIV-specific CD8(+) T cell responses
por: Borgo, Gina M., et al.
Publicado: (2023)

Strategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
por: Williams, Wilton B., et al.
Publicado: (2021)

Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development
por: Wiehe, Kevin, et al.
Publicado: (2018)

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
por: Cheeseman, Hannah M., et al.
Publicado: (2016)

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
por: Haynes, Barton F., et al.
Publicado: (2022)

Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies
por: Henderson, Rory, et al.
Publicado: (2019)

Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques
por: Shen, Xiaoying, et al.
Publicado: (2017)

A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117
por: Zacharopoulou, Panagiota, et al.
Publicado: (2022)

HIV and the eye
por: Gichuhi, Stephen, et al.
Publicado: (2020)

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
por: Kedor, Claudia, et al.
Publicado: (2020)

Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage
por: Wagh, Kshitij, et al.
Publicado: (2023)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells
por: Rao, Priyanka Gadam, et al.
Publicado: (2023)

Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies
por: Kim, Soohyun, et al.
Publicado: (2022)

Effect of rapid HIV testing on HIV incidence and services in populations at high risk for HIV exposure: an equity-focused systematic review
por: Pottie, Kevin, et al.
Publicado: (2014)

Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice
por: Ondondo, Beatrice, et al.
Publicado: (2014)

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis
por: Wills, Saintedym, et al.
Publicado: (2018)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells
por: Cohen, Yehuda Z., et al.
Publicado: (2018)

Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa
por: Loxton, André G., et al.
Publicado: (2017)

Mortality in HIV-infected patients with tuberculosis treated with streptomycin and a two-week intensified regimen: data from an HIV cohort study using inverse probability of treatment weighting
por: Alvarez-Uria, Gerardo, et al.
Publicado: (2016)

Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease
por: El-Far, Mohamed, et al.
Publicado: (2018)

PRETERM BIRTH AND FETAL GROWTH RESTRICTION IN HIV-INFECTED BRAZILIAN PREGNANT WOMEN
por: dos REIS, Helena Lucia Barroso, et al.
Publicado: (2015)

Lessons from acute HIV infection
por: Robb, Merlin L., et al.
Publicado: (2016)

2019 John M. Eisenberg Patient Safety and Quality Awards: An Interview with Gordon D. Schiff
por: Graber, Interviewed by Mark L.
Publicado: (2020)

DETERMINATION OF VIRAL TROPISM BY GENOTYPING AND PHENOTYPING ASSAYS IN BRAZILIAN HIV-1-INFECTED PATIENTS
por: Arruda, Liã Bárbara, et al.
Publicado: (2014)

Harm reduction interventions in HIV care: a qualitative exploration of patient and provider perspectives
por: Carlberg-Racich, Suzanne
Publicado: (2016)

Clusters of sub-Saharan African countries based on sociobehavioural characteristics and associated HIV incidence
por: Merzouki, Aziza, et al.
Publicado: (2021)

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
por: Yates, Nicole L., et al.
Publicado: (2018)

Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007
por: Biraro, Samuel, et al.
Publicado: (2013)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study
por: Aboud, M, et al.
Publicado: (2010)

A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model
por: Nakagawa, Fumiyo, et al.
Publicado: (2016)

Older adults at high risk of HIV infection in China: a systematic review and meta-analysis of observational studies
por: Wang, Yuan Yuan, et al.
Publicado: (2020)

Estimated blood pressure trajectories and hypertension patterns among pregnant women living with HIV, Haiti, 2007–2017
por: Tymejczyk, Olga, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
por: Yang, Xueying, et al.
Publicado: (2022)

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
por: Beltran-Pavez, Carolina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_657p8u1rhf87bipulrbm5ad29s